Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.27 -2.4%	$3.33	$2.30 ▼ $4.73	$619.64M	1.93	1.03 million shs	1.44 million shs
ALNY Alnylam Pharmaceuticals	$271.02 +0.7%	$259.42	$141.98 ▼ $304.39	$35.09B	0.39	811,079 shs	984,089 shs
BNTX BioNTech	$95.40 -0.5%	$111.75	$76.53 ▼ $131.49	$22.89B	0.3	788,772 shs	722,296 shs
CVAC CureVac	$2.80 -1.8%	$3.43	$2.22 ▼ $5.28	$626.86M	2.53	810,911 shs	544,494 shs
PFE Pfizer	$25.05 -0.6%	$26.12	$24.48 ▼ $31.54	$142.08B	0.61	36.82 million shs	51.26 million shs

The 10 Best Stocks to Own: Spring 2025

Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-0.59%	+1.21%	+0.30%	+5.02%	+34.54%
ALNY Alnylam Pharmaceuticals	-4.18%	+6.22%	+8.14%	+11.01%	+77.15%
BNTX BioNTech	-1.18%	-3.39%	-18.02%	-15.71%	+4.58%
CVAC CureVac	-2.06%	-6.25%	-12.84%	-6.56%	-3.06%
PFE Pfizer	-1.44%	-3.76%	-5.54%	-5.15%	-8.69%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.6503 of 5 stars	3.5	0.0	0.0	0.0	2.8	0.8	0.6
ALNY Alnylam Pharmaceuticals	4.2621 of 5 stars	3.4	3.0	0.0	4.3	2.6	2.5	0.6
BNTX BioNTech	2.5994 of 5 stars	4.4	2.0	0.0	0.0	2.7	0.8	0.0
CVAC CureVac	4.0007 of 5 stars	3.1	2.0	0.0	4.8	3.3	0.0	1.3
PFE Pfizer	4.9874 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	68.20% Upside
ALNY Alnylam Pharmaceuticals	2.76	Moderate Buy	$312.30	15.23% Upside
BNTX BioNTech	2.89	Moderate Buy	$143.73	50.66% Upside
CVAC CureVac	2.25	Hold	$10.00	257.14% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	27.43% Upside

Current Analyst Ratings Breakdown

Latest PFE, ALNY, ABUS, BNTX, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/24/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$280.00 ➝ $328.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$338.00 ➝ $351.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$385.00 ➝ $390.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$310.00 ➝ $330.00
3/21/2025	ALNY Alnylam Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/21/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$300.00 ➝ $338.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$275.00 ➝ $287.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00
3/21/2025	ALNY Alnylam Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$302.00 ➝ $325.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.74M	91.91	N/A	N/A	$0.63 per share	5.19
ALNY Alnylam Pharmaceuticals	$2.25B	15.61	N/A	N/A	$0.52 per share	521.19
BNTX BioNTech	$2.75B	8.32	$4.10 per share	23.25	$92.17 per share	1.04
CVAC CureVac	$543.28M	1.15	N/A	N/A	$2.50 per share	1.12
PFE Pfizer	$63.63B	2.23	$3.93 per share	6.38	$15.81 per share	1.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$72.85M	-$0.43	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	3/27/2025 (Estimated)
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.17	N/A	304.52	N/A	-12.37%	N/A	-6.83%	5/1/2025 (Estimated)
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
CVAC CureVac	-$281.58M	$0.55	5.09	N/A	N/A	20.72%	21.98%	15.72%	4/23/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.77	8.27	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)

Latest PFE, ALNY, ABUS, BNTX, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/23/2025	N/A	CVAC CureVac	$0.27	N/A	N/A	N/A	$20.58 million	N/A
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.0750	+$0.0050	-$0.07	$2.20 million	$1.57 million
3/10/2025	Q4 24	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/13/2025	Q4 2024	ALNY Alnylam Pharmaceuticals	-$0.62	-$0.65	-$0.03	-$0.65	$580.62 million	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.60%	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.87%	+2.50%	121.99%	16 Years

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	7.02	7.02
ALNY Alnylam Pharmaceuticals	15.27	2.78	2.71
BNTX BioNTech	0.01	7.33	7.21
CVAC CureVac	0.05	6.20	6.19
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ALNY Alnylam Pharmaceuticals	92.97%
BNTX BioNTech	15.52%
CVAC CureVac	17.26%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	4.00%
ALNY Alnylam Pharmaceuticals	1.50%
BNTX BioNTech	19.20%
CVAC CureVac	2.15%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	189.49 million	181.91 million	Optionable
ALNY Alnylam Pharmaceuticals	2,000	129.46 million	127.52 million	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
CVAC CureVac	880	223.88 million	219.07 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable

PFE, ALNY, ABUS, BNTX, and CVAC Headlines

Recent News About These Companies

Pfizer: Value Play or Past Its Prime?

March 27 at 8:04 PM | fool.com

Pfizer (PFE) Under Fire for Massive Tax Avoidance Allegations

March 27 at 6:49 PM | gurufocus.com

Is Pfizer Inc.'s (NYSE:PFE) Recent Price Movement Underpinned By Its Weak Fundamentals?

March 27 at 3:30 PM | uk.finance.yahoo.com

WSJ report of probe to have limited impact on Pfizer, says Citi

March 27 at 3:30 PM | markets.businessinsider.com

Pfizer ran what could be the largest tax dodging scheme among Big Pharma: Senator

March 27 at 3:30 PM | msn.com

Pfizer (NYSE:PFE) Trading Down 0.2% - What's Next?

March 27 at 12:41 PM | marketbeat.com

U.S. prosecutors look into claim Pfizer delayed vaccine news, WSJ says

March 27 at 10:28 AM | markets.businessinsider.com

Did Pfizer Delay Covid Vaccine Announcement Until After 2020 Election? Here's What We Know.

March 27 at 10:05 AM | forbes.com

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

March 27 at 7:49 AM | financialpost.com

Norges Bank Takes $2.33 Billion Position in Pfizer Inc. (NYSE:PFE)

March 27 at 7:31 AM | marketbeat.com

Caisse Des Depots ET Consignations Acquires Shares of 304,689 Pfizer Inc. (NYSE:PFE)

March 27 at 7:29 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Stake Raised by Delta Asset Management LLC TN

March 27 at 6:50 AM | marketbeat.com

Why Pfizer Is My Largest Healthcare Position

March 27 at 6:45 AM | fool.com

AssuredPartners Investment Advisors LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

March 27 at 6:41 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Acquired by NEOS Investment Management LLC

March 27 at 6:40 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Amica Mutual Insurance Co.

March 27 at 6:39 AM | marketbeat.com

Elo Mutual Pension Insurance Co Trims Holdings in Pfizer Inc. (NYSE:PFE)

March 27 at 6:14 AM | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Has $239.66 Million Stock Position in Pfizer Inc. (NYSE:PFE)

March 27 at 6:05 AM | marketbeat.com

Korea Investment CORP Acquires 465,700 Shares of Pfizer Inc. (NYSE:PFE)

March 27 at 5:54 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by UNIVEST FINANCIAL Corp

March 27 at 5:25 AM | marketbeat.com

Modern Wealth Management LLC Raises Position in Pfizer Inc. (NYSE:PFE)

March 27 at 4:58 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFE, ALNY, ABUS, BNTX, and CVAC Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.27 -0.08 (-2.39%)

Closing price 04:00 PM Eastern

Extended Trading

$3.27 0.00 (0.00%)

As of 06:21 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Alnylam Pharmaceuticals NASDAQ:ALNY

$271.02 +1.81 (+0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$257.76 -13.26 (-4.89%)

As of 07:04 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BioNTech NASDAQ:BNTX

$95.40 -0.50 (-0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$95.68 +0.27 (+0.29%)

As of 07:31 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

CureVac NASDAQ:CVAC

$2.80 -0.05 (-1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$3.02 +0.23 (+8.04%)

As of 07:53 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Pfizer NYSE:PFE

$25.05 -0.16 (-0.63%)

Closing price 03:59 PM Eastern

Extended Trading

$25.05 0.00 (0.00%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time